Cardiovascular therapeutics
-
Randomized Controlled Trial
A randomized study of the relative pharmacokinetics, pharmacodynamics, and safety of alirocumab, a fully human monoclonal antibody to PCSK9, after single subcutaneous administration at three different injection sites in healthy subjects.
We investigated the relative pharmacokinetics, pharmacodynamics, and safety of the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor alirocumab following injection at three different sites. ⋯ These results suggest that alirocumab can be interchangeably injected in the abdomen, upper arm, or thigh.